Home › Funds › Livforsakringsbolaget Skandia, Omsesidigt › UTHR

Livforsakringsbolaget Skandia, Omsesidigt position in UTHR

UNITED THERAPEUTICS CORP DEL · Health Care

Livforsakringsbolaget Skandia, Omsesidigt reported holding 36,200 shares of UTHR (UNITED THERAPEUTICS CORP DEL) in its Q3 2026 13F filing — a position valued at US$19.6M, representing 0.65% of its reported portfolio and ranking #35 among its reported holdings. Livforsakringsbolaget Skandia, Omsesidigt has disclosed UTHR holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)36.20K sh
Reported value held$19.62M
Portfolio Weight0.65%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Livforsakringsbolaget Skandia, Omsesidigt's UTHR position evolved

Livforsakringsbolaget Skandia, Omsesidigt first disclosed a stake in UTHR in Q3 2023 at 16,250 shares (US$3.7M). The position peaked in Q2 2026 at 36,400 shares, worth US$19.7M. Across 13 filings, Livforsakringsbolaget Skandia, Omsesidigt increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 36,200 shares valued at US$19.6M — a reduction of -200 shares quarter over quarter.. Notable position changes include a 6925% increase in Q4 2024 (shares fell 11% over the following quarter), a 98% trim in Q2 2025 (shares rose 46% over the following quarter), a 5200% increase in Q4 2025 (shares rose 22% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 16.25K $3.66M New
Q4 2023 16.25K $3.57M Hold
Q1 2024 16.25K $3.73M Hold
Q2 2024 20.85K $6.64M Add
Q3 2024 400 $143.25K Reduce
Q4 2024 28.10K $9.90M Add
Q1 2025 21.00K $6.47M Reduce
Q2 2025 400 $114.94K Reduce
Q3 2025 400 $167.57K Hold
Q4 2025 21.20K $10.32M Add
Q1 2026 30.90K $18.32M Add
Q2 2026 36.40K $19.70M Add
Q3 2026 36.20K $19.62M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About UTHR and 13F data

UTHR (UNITED THERAPEUTICS CORP DEL) is a Health Care company. 39 other funds we track also report a position in UTHR — the largest reported positions include Avoro Capital Advisors LLC (US$1.51B), Renaissance Technologies (US$908.2M), ASSETMARK, INC (US$325.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding UTHR

All UTHR fund holders →

FAQ

How long has Livforsakringsbolaget Skandia, Omsesidigt held UTHR?

Livforsakringsbolaget Skandia, Omsesidigt has disclosed UTHR holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Livforsakringsbolaget Skandia, Omsesidigt's current position in UTHR?

As of Q3 2026, Livforsakringsbolaget Skandia, Omsesidigt holds 36.20K shares of UTHR (UNITED THERAPEUTICS CORP DEL), valued at $19.62M, representing 0.65% of its reported portfolio and ranking #35.

Has Livforsakringsbolaget Skandia, Omsesidigt been buying or selling UTHR?

In the latest 13F filing (Q3 2026), Livforsakringsbolaget Skandia, Omsesidigt reduced its position in UTHR. The position peaked in Q2 2026 at 36.40K shares.

Which other funds hold UTHR?

Other major institutional holders of UTHR include Avoro Capital Advisors LLC, Renaissance Technologies, ASSETMARK, INC, among 39 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.